Journey Medical Corp (DERM)
NASDAQ (CM) NASDAQ (CM) Primary 
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by.
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
